Technology & Software Global On demand · 24-48h

Global Noninfectious Chronic Disease (NCDs) Health Management Software Market Strategic Research Report

Global Noninfectious Chronic Disease (NCDs) Health Managemen…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Noninfectious Chronic Disease (NCDs) Health Management Software Market
$6.33B2025
9.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Cardiovascular Disease Management Type, Metabolic Disease Management Type, Respiratory Disease Management Type, Comprehensive Multi-NCD Management Type, Others

By Application: Individual Patient Management, Clinical Practice, Community Health Services, Elderly Care, Corporate Health Management, Health Insurance Management, Medical Research, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Teladoc Health, Omada Health, Welldoc, Philips Healthcare, Honeywell, Medtronic, Oracle Health, Epic Systems, Athenahealth, Veradigm, GE HealthCare, VirtualHealth, Symplr, Conduent, McKesson, Merative, HealthSnap, Huma Therapeutics, ClouDr, WeDoctor, JD Health, Alibaba Health, Ping An Good Doctor, More Health, Winning Health, Neusoft, Welby, CureApp, PHC Holdings, MICIN

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 167 pages
Market size 2025
$6.33B
Billion USD
Forecast CAGR
9.5%
2025-2032
Forecast 2032
$11.9B
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Noninfectious Chronic Disease (NCDs) Health Management Software market size is predicted to grow from US$ 6,334 million in 2025 to US$ 11,965 million in 2032; it is expected to grow at a CAGR of 9.5% from 2026 to 2032.

Noninfectious Chronic Disease (NCDs) Health Management Software is a specialized digital health tool designed to support the prevention, monitoring, and management of noninfectious chronic diseases—including cardiovascular diseases, diabetes, hypertension, chronic respiratory diseases, and cancer—by integrating patient health data, clinical guidance, and lifestyle intervention features. This software enables users (patients, healthcare providers, and caregivers) to track key health indicators (such as blood pressure, blood glucose, weight, and medication adherence), access personalized health recommendations, set health goals, and share data with medical professionals in real time. Unlike general health management apps, it is tailored to the long-term, progressive nature of NCDs, offering features such as disease-specific risk assessment, medication reminders, diet and exercise planning, and longitudinal health data analysis. It integrates with wearable devices, electronic medical records (EMRs), and telemedicine platforms, serving as a comprehensive solution to empower patients to take an active role in their health, assist healthcare providers in delivering personalized care, and reduce the burden of NCDs on healthcare systems.

The demand for Noninfectious Chronic Disease (NCDs) Health Management Software is growing rapidly, driven by the global rise in the prevalence of NCDs (which account for over 70% of global deaths), the increasing emphasis on preventive healthcare and patient self-management, the aging global population, and the digital transformation of healthcare systems. Demand is concentrated in regions with high NCD rates and advanced digital health infrastructure, including North America, Europe, and Asia-Pacific—Asia-Pacific is the fastest-growing market due to its large aging population, rising NCD prevalence, and expanding access to digital health tools. Key users include patients with chronic diseases, healthcare providers (general practitioners, specialists), healthcare facilities (hospitals, community health centers), and insurance companies, with needs ranging from basic self-monitoring tools for patients to advanced, AI-powered solutions for healthcare providers that support risk stratification and personalized intervention. This demand presents substantial business opportunities: software developers can invest in R&D to enhance AI-driven features (e.g., predictive risk assessment, personalized treatment recommendations), integrate with a wider range of wearable devices and EMR systems, and develop disease-specific modules (e.g., diabetes-focused, cardiovascular-focused) to cater to niche needs. Additionally, providing user-friendly interfaces for elderly and chronically ill users, ensuring data security and regulatory compliance (e.g., HIPAA, GDPR), and offering telemedicine integration for remote consultations can unlock further market potential. As global healthcare systems shift toward proactive, patient-centered care, the long-term demand for NCDs health management software will remain strong, with the market projected to grow at a double-digit CAGR in the coming years.

This report presents a comprehensive overview of the global Noninfectious Chronic Disease (NCDs) Health Management Software market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Applicable NCD Type

  • Cardiovascular Disease Management Type
  • Metabolic Disease Management Type
  • Respiratory Disease Management Type
  • Comprehensive Multi-NCD Management Type
  • Others

Segment by Data Integration Capability

  • Basic Integration Type
  • Multi-source Integration Type
  • Advanced Integration Type
  • Others

Segment by Deployment Mode

  • Cloud-based Type
  • On-premises Type
  • Hybrid Type

Segment by Application

  • Individual Patient Management
  • Clinical Practice
  • Community Health Services
  • Elderly Care
  • Corporate Health Management
  • Health Insurance Management
  • Medical Research
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Noninfectious Chronic Disease (NCDs) Health Management Software market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Individual Patient Management, Clinical Practice, Community Health Services evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Noninfectious Chronic Disease (NCDs) Health Management Software Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$6.33B
2025
Forecast
$11.9B
2032
CAGR
9.5%
2025–2032
Regiões
5
global
Key companies
Teladoc HealthOmada HealthWelldocPhilips HealthcareHoneywellMedtronicOracle HealthEpic Systems
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Cardiovascular Disease Management TypeMetabolic Disease Management TypeRespiratory Disease Management TypeComprehensive Multi-NCD Management TypeOthers
By Application
Individual Patient ManagementClinical PracticeCommunity Health ServicesElderly CareCorporate Health ManagementHealth Insurance ManagementMedical ResearchOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Cardiovascular Disease Management Type
  • 3.1.3 Metabolic Disease Management Type
  • 3.1.4 Respiratory Disease Management Type
  • 3.1.5 Comprehensive Multi-NCD Management Type
  • 3.1.6 Others
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Individual Patient Management
  • 4.1.3 Clinical Practice
  • 4.1.4 Community Health Services
  • 4.1.5 Elderly Care
  • 4.1.6 Corporate Health Management
  • 4.1.7 Health Insurance Management
  • 4.1.8 Medical Research
  • 4.1.9 Others
  • 4.1.10 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Teladoc Health
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Omada Health
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Welldoc
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Philips Healthcare
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Honeywell
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Medtronic
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Oracle Health
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Epic Systems
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Athenahealth
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Veradigm
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 GE HealthCare
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 VirtualHealth
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Symplr
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Conduent
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 McKesson
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Merative
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 HealthSnap
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Huma Therapeutics
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 ClouDr
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 WeDoctor
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 JD Health
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Alibaba Health
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Ping An Good Doctor
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 More Health
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Winning Health
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Neusoft
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Welby
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 CureApp
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 PHC Holdings
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 MICIN
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Noninfectious Chronic Disease (NCDs) Health Management Software market?
The global Noninfectious Chronic Disease (NCDs) Health Management Software market is estimated at US$ 6.33 billion in 2025 (base year) and is projected to reach US$ 11.96 billion by 2032.
What is the forecast CAGR for the Noninfectious Chronic Disease (NCDs) Health Management Software market?
The market is expected to grow at a CAGR of 9.5% from 2026 to 2032, expanding from US$ 6.33 billion in 2025 to US$ 11.96 billion in 2032, roughly 1.9 times its base-year value.
What is Noninfectious Chronic Disease (NCDs) Health Management Software?
Noninfectious Chronic Disease (NCDs) Health Management Software is a specialized digital health tool designed to support the prevention, monitoring, and management of noninfectious chronic diseases—including cardiovascular diseases, diabetes, hypertension, chronic respiratory diseases, and cancer—by integrating patient health data, clinical guidance, and lifestyle intervention features.
What are the main segments of the Noninfectious Chronic Disease (NCDs) Health Management Software market by applicable ncd type?
By applicable ncd type, the market is segmented into Cardiovascular Disease Management Type, Metabolic Disease Management Type, Respiratory Disease Management Type, Comprehensive Multi-NCD Management Type and Others.
Which applications drive demand in the Noninfectious Chronic Disease (NCDs) Health Management Software market?
Key applications covered include Individual Patient Management, Clinical Practice, Community Health Services, Elderly Care, Corporate Health Management, Health Insurance Management, Medical Research and Others.
Who are the key players in the Noninfectious Chronic Disease (NCDs) Health Management Software market?
Key players profiled include Teladoc Health, Omada Health, Welldoc, Philips Healthcare, Honeywell, Medtronic, Oracle Health and Epic Systems, among 30 companies covered in total.
Which regions and countries are covered for Noninfectious Chronic Disease (NCDs) Health Management Software?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Noninfectious Chronic Disease (NCDs) Health Management Software market?
The demand for Noninfectious Chronic Disease (NCDs) Health Management Software is growing rapidly, driven by the global rise in the prevalence of NCDs (which account for over 70% of global deaths), the increasing emphasis on preventive healthcare and patient self-management, the aging global population, and the digital transformation of healthcare systems.
Who should buy the Noninfectious Chronic Disease (NCDs) Health Management Software market report?
The report is intended for manufacturers and solution providers, distributors and end users in Individual Patient Management, Clinical Practice and Community Health Services, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Noninfectious Chronic Disease (NCDs) Health Management Software market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.